Mdm2 has been shown to promote its own ubiquitination and the ubiquitinatio
n of the p53 tumour suppressor by virtue of its E3 ubiquitin ligase activit
y. This modification targets Mdm2 and p53 for degradation by the proteasome
. The p14ARF tumour suppressor has been shown to inhibit degradation of p53
mediated by Mdm2. Several models have been proposed to explain this effect
of p14ARF. Here we have compared the effects of p14ARF overexpression on t
he in vivo ubiquitination of p53 and Mdm2. We report that the inhibition of
the Mdm2-mediated degradation of p53 by p14ARF is associated with a decrea
se in the proportion of ubiquitinated p53. The levels of polyubiquitinated
p53 decreased preferentially compared to monoubiquitinated species. p14ARF
overexpression increased the levels of Mdm2 but it did not reduce the overa
ll levels of ubiquitinated Mdm2 in vivo. This is unexpected because p14ARF
has been reported to inhibit the ubiquitination of Mdm2 in vitro. In additi
on we show that like p14ARF, the proteasome inhibitor MG132 can promote the
accumulation of Mdm2 in the nucleolus and that this can occur in the absen
ce of p14ARF expression. We also show that the mutation of the nucleolar lo
calization signal of Mdm2 does not impair the overall ubiquitination of Mdm
2 but is necessary for the effective polyubiquitination of p53. These studi
es reveal important differences in the regulation of the stability of p53 a
nd of Mdm2.